NervGen Pharma (TSE:NGEN) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NervGen Pharma is nearing the completion of the target enrollment for its Phase 1b/2a clinical trial of NVG-291, a new treatment aimed at repairing nervous system damage from spinal cord injuries. The trial has attracted interest due to its innovative approach and is partially funded by a grant from Wings for Life. Results will focus on motor function improvements, with comprehensive assessments including clinical outcomes and electrophysiological measures.
For further insights into TSE:NGEN stock, check out TipRanks’ Stock Analysis page.